Gina Mauro

Phase 3 results from a cohort of patients in China show a progression-free survival benefit with entinostat/exemestane.

During a press briefing ahead of the 2021 San Antonio Breast Cancer Symposium, results from the phase 3 EMERALD trial were presented.

In patients with CLL who were treated with venetoclax, acalabrutinib, and obinutuzumab, Cell-free DNA–based minimal residual disease testing was found to be feasible.

Findings from the phase 1/2 trial of mobocertinib show clinical activity in a subset of patients with EGFR exon 20-positive non–small cell lung cancer.

Data from the phase 3 POSEIDON trial were presented during the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer.

Findings from the phase 1 MonumenTAL-1 trial demonstrate the clinical activity of talquetamab in patients with relapsed or refractory multiple myeloma.

Results from the phase 4 MITO-BCG study show safety of sequential mitomycin with BCG for the treatment of high-risk muscle invasive bladder cancer.

Exploratory results from the phase 3 IMpower010 trial look positive fo the use of adjuvant atezolizumab in various non–small cell lung cancer populations.

The combination of nivolumab/ipilimumab did not significantly improve OS compared with chemotherapy in patients with advanced gastric, gastroesophageal junction, or esophageal cancer.

In Western patients with HER2-positive gastric/gastroesophageal junction cancer Fam-trastuzumab deruxtecan-nxki as a second-line treatment elicited a 38% confirmed objective response rate.

Pathological complete response rates and event-free survival in patients with treatment-naïve triple-negative breast cancer were improved with The addition of carboplatin to neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide.

An impressive disease-free survival benefit was seen in patients with clear cell renal cell carcinoma with pembrolizumab as an adjuvant therapy following nephrectomy compared with placebo. This improvement was observed across subgroups.

Patients with microsatellite instability–high or mismatch repair–deficient prostate cancer may be more likely to respond to treatment with checkpoint inhibitors compared with those who have high tumor mutational burden.

Results from a phase 1/2 study showed a high rate of objective response with mobocertinib in a subset of patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer.

Data from the phase 1/2 BRUIN clinical trial showed a 62% objective response rate with responses increasing over time.

Efficacy and safety have been demonstrated with the combination of durvalumab with tremelimumab and transcatheter arterial chemoembolization or radiofrequency ablation in advanced hepatocellular carcinoma.

IMPROVED OVERALL and progres-sion-free survival rates were reported for the maintenance frontline combination of avelumab and best supportive care versus BSC alone across subgroups of patients with advanced urothelial cancer.

Patients with relapsed/refractory acute myeloid leukemia will now be assesses with the off-the-shelf cell therapy CYNK-001 after a case of conversion to minimal residual disease negativity at its highest dose level.

First-in-human results of a phase 1 trial (NCT03319940) evaluating AMG 757 in patients with small cell lung cancer revealed early signals of efficacy and a favorable safety profile in findings presented at the European Lung Cancer Virtual Congress 2021.

The time to initiate durvalumab treatment following chemoradiation was delayed in the real-world setting trial PACIFIC-R (NCT02125461) compared with the earlier phase 3 PACIFIC trial.

Without requiring red blood cell transfusions, luspatercept-aamt led to a mean increase in hemoglobin from baseline levels in 77.1% of patients compared with in 0% treated with placebo in patients with non-transfusion–dependent β-thalassemia in the phase 2 BEYOND trial, according to a presentation during the European Hematology Association 2021 Virtual Congress.

Pimitespib, a heat shock protein 90 inhibitor doubled the progression-free survival and prolonged the overall survival compared with placebo in patients with advanced gastrointestinal stromal tumor that is refractory to imatinib, sunitinib, and regorafenib, according to results from the phase 3 CHAPTER-GIST-301 trial.

In patients with ERBB2/ERBB3-expressed, mutated, or -amplified uterine cancer, the combination of pertuzumab and trastuzumab led to a 37% disease control rate, according to results from the Targeted Agent Profiling and Utilization Registry study.

Looking at 6.5 years of follow-up data from the phase 3 CheckMate-067 trial shows maintained outcomes in patients with advanced melanoma on nivolumab alone, or with ipilimumab.

No clinical activity was elicited by selumetinib in pediatric and young adult patients with refractory cancers.

Updated results from the phase 2 CodeBreaK100 trial were presented by Ferdinandos Skoulidis, MD, PhD during the 2021 ASCO Annual Meeting.

Across several previously unreported subgroups of patients with advanced urothelial cancer who have progressed on first-line platinum-containing chemotherapy avelumab as frontline maintenance plus best supportive care demonstrated a survival benefit compared with BSC alone.

Data from the phase 3 KEYNOTE-564 trial presented in a press briefing ahead of the 2021 ASCO Annual Meeting showed that adjuvant pembrolizuumab achieved significant disease-free survival improvement compared with placebo.

AB-205 demonstrated robust effects and an encouraging safety profile in patients with systemic lymphoma undergoing high-dose therapy and autologous hematopoietic stem cell transplantation.

Patients with relapsed or refractory aggressive large B-cell lymphoma showed promising results from the administration of lisocabtagene maraleucel in both inpatient and outpatient non–university hospital settings.